DE3516119C2 - - Google Patents
Info
- Publication number
- DE3516119C2 DE3516119C2 DE3516119A DE3516119A DE3516119C2 DE 3516119 C2 DE3516119 C2 DE 3516119C2 DE 3516119 A DE3516119 A DE 3516119A DE 3516119 A DE3516119 A DE 3516119A DE 3516119 C2 DE3516119 C2 DE 3516119C2
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- gram
- coli
- negative
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 241000588724 Escherichia coli Species 0.000 claims abstract description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 18
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 18
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract 5
- 239000008280 blood Substances 0.000 claims abstract 5
- 238000007796 conventional method Methods 0.000 claims abstract 2
- 244000052616 bacterial pathogen Species 0.000 claims description 19
- 210000002381 plasma Anatomy 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000002616 plasmapheresis Methods 0.000 claims description 4
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 10
- 241000589516 Pseudomonas Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- 108010044316 Cohn fraction III Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853516119 DE3516119A1 (de) | 1985-05-04 | 1985-05-04 | Polyvalentes hyperimmunglobulin-praeparat |
| DE8686105706T DE3688100D1 (de) | 1985-05-04 | 1986-04-25 | Polyvalentes hyperimmunglobulin-praeparat. |
| EP86105706A EP0201004B1 (de) | 1985-05-04 | 1986-04-25 | Polyvalentes Hyperimmunglobulin-Präparat |
| AT86105706T ATE87216T1 (de) | 1985-05-04 | 1986-04-25 | Polyvalentes hyperimmunglobulin-praeparat. |
| JP61102222A JPH0667852B2 (ja) | 1985-05-04 | 1986-05-06 | 多価高度免疫グロブリン製剤およびその製法 |
| US07/370,118 US4965068A (en) | 1985-05-04 | 1989-06-23 | Polyvalent hyperimmunoglobulin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853516119 DE3516119A1 (de) | 1985-05-04 | 1985-05-04 | Polyvalentes hyperimmunglobulin-praeparat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3516119A1 DE3516119A1 (de) | 1986-11-06 |
| DE3516119C2 true DE3516119C2 (enExample) | 1993-07-01 |
Family
ID=6269874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853516119 Granted DE3516119A1 (de) | 1985-05-04 | 1985-05-04 | Polyvalentes hyperimmunglobulin-praeparat |
| DE8686105706T Expired - Fee Related DE3688100D1 (de) | 1985-05-04 | 1986-04-25 | Polyvalentes hyperimmunglobulin-praeparat. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8686105706T Expired - Fee Related DE3688100D1 (de) | 1985-05-04 | 1986-04-25 | Polyvalentes hyperimmunglobulin-praeparat. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4965068A (enExample) |
| EP (1) | EP0201004B1 (enExample) |
| JP (1) | JPH0667852B2 (enExample) |
| AT (1) | ATE87216T1 (enExample) |
| DE (2) | DE3516119A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0374296B1 (en) * | 1988-12-22 | 1995-02-01 | Dade International Inc. | Lipohaptens and use of carrier-bound lipohaptens in immunoassays |
| US5093117A (en) * | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| EP0575517A1 (en) * | 1991-03-15 | 1993-12-29 | Univax Biologics Incorporated | Lipid a analog/immunogenic carrier conjugates, the use thereof as vaccines and polyvalent hyperimmune gammaglobulins |
| US5233024A (en) * | 1991-04-09 | 1993-08-03 | The Brigham & Women's Hospital | Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use |
| WO1994015640A1 (en) * | 1993-01-12 | 1994-07-21 | Anthony George Gristina | Methods and compositions for the direct concentrated delivery of passive immunity |
| RU2150960C1 (ru) * | 1995-07-18 | 2000-06-20 | Томский научно-исследовательский институт вакцин и сывороток НПО "Вирион" | Способ получения иммуноглобулина противодифтерийного человека |
| EP0764658B1 (de) * | 1995-09-22 | 2002-01-02 | ZLB Bioplasma AG | Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen |
| US6610293B1 (en) * | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6692739B1 (en) | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| NL1019143C2 (nl) * | 2001-10-08 | 2003-04-09 | Nutricia Nv | Farmaceutisch product of voedingssupplement en daarbij te gebruiken tussenproduct. |
| US7794720B2 (en) * | 2004-02-18 | 2010-09-14 | Plasma Ventures Pty Ltd | Isolated plasma and method for hyperimmunisation and plasma collection |
| US7935355B2 (en) * | 2007-04-19 | 2011-05-03 | Nutritional Health Institute Laboratories, Llc | Composition and method for controlling intestinal pathogenic organisms |
| US20080260777A1 (en) * | 2007-04-19 | 2008-10-23 | Sotomayor Konky | Composition and method for controlling intestinal pathogenic organisms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE14333C (de) * | P. MAC LELLAN in Glasgow | Gummimatte | ||
| BE791489A (fr) * | 1971-11-17 | 1973-05-16 | Max Planck Gesellschaft | Agent immunisant, procede de fabrication et utilisation d'un tel agent |
| US4029762A (en) * | 1971-11-17 | 1977-06-14 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Lipid A-preparation |
| US4174388A (en) * | 1977-02-14 | 1979-11-13 | Merck & Co., Inc. | Method for preparing hepatitis B immune globulin |
| US4428931A (en) * | 1982-03-15 | 1984-01-31 | Merck & Co., Inc. | Bacterial toxoids and gram-negative immune globulin therefrom |
| US4587121A (en) * | 1983-06-14 | 1986-05-06 | Miles Laboratories, Inc. | High titer Pseudomonas immune serum globulin |
-
1985
- 1985-05-04 DE DE19853516119 patent/DE3516119A1/de active Granted
-
1986
- 1986-04-25 EP EP86105706A patent/EP0201004B1/de not_active Expired - Lifetime
- 1986-04-25 DE DE8686105706T patent/DE3688100D1/de not_active Expired - Fee Related
- 1986-04-25 AT AT86105706T patent/ATE87216T1/de not_active IP Right Cessation
- 1986-05-06 JP JP61102222A patent/JPH0667852B2/ja not_active Expired - Lifetime
-
1989
- 1989-06-23 US US07/370,118 patent/US4965068A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE3516119A1 (de) | 1986-11-06 |
| JPS6230729A (ja) | 1987-02-09 |
| EP0201004A2 (de) | 1986-11-12 |
| EP0201004B1 (de) | 1993-03-24 |
| US4965068A (en) | 1990-10-23 |
| EP0201004A3 (en) | 1988-05-25 |
| ATE87216T1 (de) | 1993-04-15 |
| DE3688100D1 (de) | 1993-04-29 |
| JPH0667852B2 (ja) | 1994-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3516119C2 (enExample) | ||
| DE69230733T2 (de) | Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen | |
| DE69511245T2 (de) | Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a | |
| EP1113816A2 (de) | Influenzavirus-impfstoffzusammensetzung | |
| DE69030383T2 (de) | Impfstoff-Konjugate zur Behandlung von Vogelkrankheiten | |
| DE69419966T2 (de) | Impstoff gegen Streptococcus suis-Infektion | |
| DE3701066C2 (de) | Intravenös injizierbares Immunglobulin mit hohem Antikörpertiter gegenüber dem respiratorischen Syncytialvirus, Verfahren zu dessen Herstellung und pharmazeutische Zubereitung, welche dieses enthält | |
| AT397803B (de) | Humaner monoklonaler antikörper und hybridom zur herstellung desselben | |
| DE3882781T3 (de) | Impfstoff gegen Pasteurella. | |
| DE69005908T2 (de) | Monoklonale Antikörper zur Behandlung nach einem Kontakt mit Tollwutvirus. | |
| EP0252064B1 (de) | Gegen Pseudomonas aeruginosa Infektionen wirksame Präparationen und Verfahren zu ihrer Herstellung | |
| DE3306060A1 (de) | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung | |
| DE2639012C3 (de) | Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen | |
| DE2823750C3 (de) | Verfahren zur Gewinnung mindestens eines Hydrolyseprodukts eines Endotoxins von Bordetella Pertussis | |
| DE69126727T2 (de) | Warm-behandelte IGM-Antikörper-Zusammensetzungen | |
| DE3685700T2 (de) | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| AT410637B (de) | Verwendung von polyklonalen immunglobulinen | |
| DE1960713C3 (de) | Mehrfach-Vaccine zur gleichzeitigen Immunisierung gegen Maul- und Klauenseuche und Brucellose und gegebenenfalls gegen Tollwut | |
| DE3877102T2 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. | |
| EP0187286A1 (de) | Öladjuvierte Vaccine und Verfahren zu ihrer Herstellung | |
| DE3750725T2 (de) | GEMEINSAME IMPFUNG UNTER VERWENDUNG EINER PRAPARATION GRAM-NEGATIVER BAKTERIEN OHNE O-SPEZIFISCHEN KOHlEHYDRATSEITENKETTEN. | |
| AT390192B (de) | Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen | |
| EP0387850B1 (de) | Monoklonale, gegen ECA gerichtete Antikörper und ihre Verwendung | |
| DE1902590C2 (de) | Verwendung einer Immunribonucleinsäure (IRNS) zum Immunisieren lebender Tiere |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |